Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Blood|August 1, 1997
Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcriptionT B McNeely, D C Shugars, M Rosendahl, et al.
The Journal of Clinical Investigation|July 1, 1995
Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitroT B McNeely, M Dealy, D J Dripps, et al.
Oral Diseases|May 1, 1997
Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-IS M Wahl, T B McNeely, E N Janoff, et al.
Pharmacotherapy|November 12, 2013
Acute decompensated heart failure: evolving literature and implications for future practiceJonathan D Cicci, Brent N Reed, Elizabeth B McNeely, et al.
Vaccine|March 30, 2000
A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlersM D Blum, R Dagan, P M Mendelman, et al.
The Annals of Pharmacotherapy|January 16, 2018
Activated Factor 7 Versus 4-Factor Prothrombin Complex Concentrate for Critical Bleeding Post-Cardiac SurgerySarah L Mehringer, Zachary Klick, Jonathan Bain, et al.
The American Journal of Pathology|April 1, 1997
Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissuesS M Wahl, P Worley, W Jin, et al.
Human Vaccines & Immunotherapeutics|December 9, 2014
Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factorsTessie B McNeely, Najaf A Shah, Arthur Fridman, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 4, 2013
Relative bioavailability of tolvaptan administered via nasogastric tube and tolvaptan tablets swallowed intactElizabeth B McNeely, Jasmine A Talameh, Kirkwood F Adams, et al.
Vaccine|November 8, 2005
A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infectionRobert W Hepler, Rosemarie Kelly, Tessie B McNeely, et al.
Pageof 4